INVESTIGATORS: XXX
1. SUMMARY
TCMR0007/06
1
Cód. Protocolo: TCMR0007/06
Versión 1
XXX
Not applicable.
Phase II.
The total number of patients to be studied will be 30. The study population
will comprise both male and female patients with idiopathic dilated
cardiomyopathy.
The first patient will be included after authorisation by the Spanish Drug
Agency. The trial is due to be completed after one year of follow-up after the
inclusion of the last patient.
2. GENERAL INFORMATION
2
Cód. Protocolo: TCMR0007/06
Versión 1
2.1. Trial information
TCMR0007/06
Dr. XXX, Haematologist, Responsible for the Cryobiology and Cell Therapy
Laboratory
Hospital Universitario Reina Sofía, Córdoba
Telephone No.: XXX FAX XXX
e-mail: XXX
3
Cód. Protocolo: TCMR0007/06
Versión 1
Dr. XXX, Head of Haematology
Dr. XXX, Head of Cardiology
Dr. XXX, Head of Cardiology
Dr. XXX, Cardiologist
Dr. XXX, Radiologist
Dr. XXX, Haematologist
Dr. XXX, Cardiologist
Dr. XXX, Cardiologist
3.1. Introduction
In the last five years, we have witnessed a veritable boom in the application
of cell biology to therapy for different diseases, with important breakthroughs
related to our knowledge of stem cells.
The fact that stem cells are found in most adult tissues and that these cells
can help repair or regenerate tissue damage is an extremely attractive finding that
has revolutionised regenerative medicine applied to different fields of study. In
particular, we have greatly advanced in translational research applying basic
biological findings to the human clinical setting in relation to heart disease. This
may be because of the fact that changes in heart function are relatively easy to
measure and of the great interest in cardiovascular disease in view of its impact
and high morbidity and mortality rates.
4
Cód. Protocolo: TCMR0007/06
Versión 1
TM
INVESTIGADORES PRINCIPALES:
INVESTIGADORES:
1. RESUMEN
TCMR0007/06
5
Cód. Protocolo: TCMR0007/06
Versión 1
CEIC R.D. 561/93 / CLEC Decreto 232/02 CCAA ANDALUCIA Hospital
Universitario “Reina Sofía”.
XXX
No procede.
Fase II.
6
Cód. Protocolo: TCMR0007/06
Versión 1
El primer paciente se incluirá previa autorización de la Agencia Española de
Medicamentos y Productos Sanitarios (AEMPS). El estudio finalizará
transcurrido un año de seguimiento tras la inclusión del último paciente.
2. INFORMACIÓN GENERAL
TCMR0007/06
7
Cód. Protocolo: TCMR0007/06
Versión 1
Dra. XXX, FEA de Hematología, responsable del Laboratorio de Criobiología y
Terapia Celular
Hospital Universitario Reina Sofía, Córdoba.
3. JUSTIFICACIÓN Y OBJETIVOS
3.1. Introducción
8
Cód. Protocolo: TCMR0007/06
Versión 1